A Phase I Trial of p28 (Cell Penetrating Peptide) in the Treatment of Refractory Solid Tumors
The purpose of this study is to evaluate the safety of an experimental drug (p28) as a treatment for certain advanced cancers which express a protein called p53 and which have not responded to prior treatment.
100 项与 CDG Therapeutics, Inc. 相关的临床结果
0 项与 CDG Therapeutics, Inc. 相关的专利(医药)
100 项与 CDG Therapeutics, Inc. 相关的药物交易
100 项与 CDG Therapeutics, Inc. 相关的转化医学